Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

CorrigendumHematology Free access | 10.1172/JCI21716C1

EVI1 induces myelodysplastic syndrome in mice

Silvia Buonamici, Donglan Li, Yiqing Chi, Rui Zhao, Xuerong Wang, Larry Brace, Hongyu Ni, Yogen Saunthararajah, and Giuseppina Nucifora

Find articles by Buonamici, S. in: PubMed | Google Scholar

Find articles by Li, D. in: PubMed | Google Scholar

Find articles by Chi, Y. in: PubMed | Google Scholar

Find articles by Zhao, R. in: PubMed | Google Scholar

Find articles by Wang, X. in: PubMed | Google Scholar

Find articles by Brace, L. in: PubMed | Google Scholar

Find articles by Ni, H. in: PubMed | Google Scholar

Find articles by Saunthararajah, Y. in: PubMed | Google Scholar

Find articles by Nucifora, G. in: PubMed | Google Scholar

Published August 1, 2005 - More info

Published in Volume 115, Issue 8 on August 1, 2005
J Clin Invest. 2005;115(8):2296–2296. https://doi.org/10.1172/JCI21716C1.
© 2005 The American Society for Clinical Investigation
Published August 1, 2005 - Version history
View PDF

Related article:

EVI1 induces myelodysplastic syndrome in mice
Silvia Buonamici, … , Yogen Saunthararajah, Giuseppina Nucifora
Silvia Buonamici, … , Yogen Saunthararajah, Giuseppina Nucifora
Article Hematology

EVI1 induces myelodysplastic syndrome in mice

  • Text
  • PDF
Abstract

Myelodysplasia is a hematological disease in which genomic abnormalities accumulate in a hematopoietic stem cell leading to severe pancytopenia, multilineage differentiation impairment, and bone marrow (BM) apoptosis. Mortality in the disease results from pancytopenia or transformation to acute myeloid leukemia. There are frequent cytogenetic abnormalities, including deletions of chromosomes 5, 7, or both. Recurring chromosomal translocations in myelodysplasia are rare, but the most frequent are the t(3;3)(q21;q26) and the inv(3)(q21q26), which lead to the inappropriate activation of the EVI1 gene located at 3q26. To better understand the role of EVI1 in this disease, we have generated a murine model of EVI1-positive myelodysplasia by BM infection and transplantation. We find that EVI1 induces a fatal disease of several stages that is characterized by severe pancytopenia. The disease does not progress to acute myeloid leukemia. Comparison of in vitro and in vivo results suggests that EVI1 acts at two levels. The immediate effects of EVI1 are hyperproliferation of BM cells and downregulation of EpoR and c-Mpl, which are important for terminal erythroid differentiation and platelet formation. These defects are not fatal, and the mice survive for about 10 months with compensated hematopoiesis. Over this time, compensation fails, and the mice succumb to fatal peripheral cytopenia.

Authors

Silvia Buonamici, Donglan Li, Yiqing Chi, Rui Zhao, Xuerong Wang, Larry Brace, Hongyu Ni, Yogen Saunthararajah, Giuseppina Nucifora

×

Original citation: J. Clin. Invest.114:713–719 (2004). doi:10.1172/JCI21716

Citation for this corrigendum: J. Clin. Invest.115:2296 (2005). doi:10.1172/JCI21716C1

Credit to the co-first authors was omitted from the original manuscript. The following footnote should have appeared after the corresponding author's address.

Silvia Buonamici and Donglan Li contributed equally to this manuscript.

The authors regret this error.

Version history
  • Version 1 (August 1, 2005): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts